{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T16:22:20Z","timestamp":1773073340655,"version":"3.50.1"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T00:00:00Z","timestamp":1757980800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Multiple myeloma (MM) is a malignant plasma cell disorder characterized by the clonal expansion of abnormal plasma cells within the bone marrow. The management of relapsed\/refractory multiple myeloma (RRMM) represents a significant challenge as the disease relapses or becomes refractory to previous treatments. Recent advances in therapy have expanded RRMM treatment options. This study aimed to gain a deeper understanding of patients' treatment preferences regarding available therapeutic options.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study was designed as a non-interventional descriptive cross-sectional study based on an online discrete choice experiment (DCE) among adult RRMM patients living in the between USA November 2023 and March 2024. The survey included attributes and levels derived from an extensive literature review and guided interviews conducted with MM patients. Preference data were analyzed using a conditional logistic (CL) regression model and relative attribute importance (RAI) scores were calculated. Patients\u2019 willingness to trade off overall response rate (ORR) was evaluated using the partworth utilities estimated from the CL model.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>149 MM patients completed the survey; 66% had received 1\u20132 prior lines of therapy, 15% three prior lines, 19% four or more prior lines. Patients significantly preferred treatments with longer progression-free survival (PFS) and overall survival (OS) and higher ORR (RAI: 36.4% and 22.1%, respectively). With respect to adverse events assessed in this study, patients expressed concern for cytokine release syndrome (CRS) (RAI: 15.2%) and infections (RAI: 11.9%). In contrast, nail\/skin disorders, duration of hospitalization, and taste disorder were less important to patients. Patients would be willing to accept a high risk of CRS (72% over no risk) to gain 29% increase in ORR.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Patients showed a clear preference for treatment efficacy (PFS\/OS and ORR). This study confirmed patients\u2019 valuation on treatment attributes in the new treatment landscape and highlighted the importance of shared treatment decision-making for optimal clinical outcomes.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1628121","type":"journal-article","created":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T04:12:22Z","timestamp":1757995942000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["A discrete choice experiment analysis to understand patient preferences for multiple myeloma treatments"],"prefix":"10.3389","volume":"15","author":[{"given":"Beth","family":"Faiman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hoa H.","family":"Le","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Laurent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saurabh","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agne","family":"Paner-Straseviciute","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinke","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Mikhael","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,16]]},"reference":[{"key":"B1","article-title":"Multiple myeloma","volume-title":"StatPearls","author":"Albagoush","year":"2024"},{"key":"B2","unstructured":"Cancer stat facts: myeloma - surveillance, epidemiology, and end results program"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25791","article-title":"Multiple myeloma: 2020 update on diagnosis, risk-stratification and management","volume":"95","author":"Rajkumar","year":"2020","journal-title":"Am J Hematology"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA: A Cancer J Clin"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-299487","article-title":"Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1","volume":"117","author":"Rajkumar","year":"2011","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2017.1.508","article-title":"Management of multiple myeloma in the relapsed\/refractory patient","volume":"2017","author":"Sonneveld","year":"2017","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B7","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/s41408-024-01191-8","article-title":"CAR-T cell therapy in Multiple Myeloma: current status and future challenges","volume":"14","author":"Swan","year":"2024","journal-title":"Blood Cancer J"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01338-6","article-title":"Teclistamab, a B-cell maturation antigen\u2008\u00d7\u2008CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study","volume":"398","author":"Usmani","year":"2021","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(24)00976-5","article-title":"Long-term efficacy and safety results from the phase 1\/2 MonumenTAL-1 study of talquetamab, a GPRC5D\u00d7CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma","author":"Rasche","year":"2024","journal-title":"Eur Hematol Assoc (EHA)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.7505","article-title":"First-in-human study of JNJ-79635322 (JNJ-5322), a novel, next-generation trispecific antibody (TsAb), in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): Initial phase 1 results","volume":"43","author":"van de Donk","year":"2025","journal-title":"JCO"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/hec.1697","article-title":"Discrete choice experiments in health economics: a review of the literature","volume":"21","author":"de Bekker-Grob","year":"2012","journal-title":"Health Econ"},{"key":"B13","first-page":"55","article-title":"Using discrete choice experiments to value health care programmes: current practice and future research reflections","volume":"2","author":"Ryan","year":"2003","journal-title":"Appl Health Econ Health Policy"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-159707","article-title":"157 Talquetamab, a G protein-coupled receptor family C group 5 member D \u00d7CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma: phase 1\/2 results from MonumenTAL-1. American Society of Hematology Annual Meeting, Abstract 157","volume":"140","author":"Chari","year":"2022","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-162440","article-title":"Efficacy and safety of elranatamabin patients with relapsed\/refractory multiple myeloma na\u00efve to B-cell maturation antigen (BCMA)-directed therapies: results from cohort A of the magnetismm-3 study","volume":"140","author":"Bahlis","year":"2022","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-1225","article-title":"Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed\/refractory multiple myeloma","volume":"17","author":"H\u00e1jek","year":"2021","journal-title":"Future Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01531-2","article-title":"LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma","volume":"36","author":"Mateos","year":"2022","journal-title":"Leukemia"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30152-4","article-title":"Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial","volume":"20","author":"Richardson","year":"2019","journal-title":"Lancet Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"112926","DOI":"10.1016\/j.ejca.2023.05.014","article-title":"Infection rates are high across the multiple myeloma continuum, not just with bispecific antibodies","volume":"189","author":"Rubinstein","year":"2023","journal-title":"Eur J Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200826080-00004","article-title":"Conducting discrete choice experiments to inform healthcare decision making","volume":"26","author":"Lancsar","year":"2008","journal-title":"PharmacoEconomics"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.320.7248.1530","article-title":"Using conjoint analysis to elicit preferences for health care","volume":"320","author":"Ryan","year":"2000","journal-title":"BMJ"},{"key":"B24","volume-title":"The R project for statistical computing: optFederov","author":"Wheeler","year":"2004"},{"key":"B25","article-title":"Getting the most from CBC","volume-title":"Sawtooth Software Research Paper Series","author":"Johnson","year":"2003"},{"key":"B26","volume-title":"Getting started with conjoint analysis: strategies for product design and pricing research","author":"Orme","year":"2006"},{"key":"B27","article-title":"Conditional logit analysis of qualitative choice behavior","volume-title":"Frontiers in econometrics","author":"McFadden","year":"1973"},{"key":"B28","volume-title":"Getting started with conjoint analysis: Strategies for product design and pricing research","author":"Orme","year":"2006"},{"key":"B29","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1111\/bjh.18654","article-title":"Relapsed and refractory multiple myeloma: A systematic review and network meta-analysis of the efficacy of novel therapies","volume":"200","author":"Minakata","year":"2023","journal-title":"Br J Haematol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.686165","article-title":"Patient preferences for multiple myeloma treatments: A multinational qualitative study","volume":"8","author":"Janssens","year":"2021","journal-title":"Front Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30756-7","article-title":"Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group","volume":"22","author":"Moreau","year":"2021","journal-title":"Lancet Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1271657","article-title":"Treatment preferences of patients with relapsed or refractory multiple myeloma in the United States, United Kingdom, Italy, Germany, France, and Spain: results from a discrete choice experiment","volume":"10","author":"Thomas","year":"2023","journal-title":"Front Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1182\/blood.V126.23.2086.2086","article-title":"Assessment of multiple myeloma patient preferences on treatment choices: an international discrete choice study","volume":"126","author":"Leleu","year":"2015","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2023.01.016","article-title":"Current health state affected patient preferences more than disease status: A discrete choice experiment in multiple myeloma","volume":"26","author":"Tervonen","year":"2023","journal-title":"Value Health"},{"key":"B35","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1186\/s12885-020-07018-6","article-title":"Alignment of preferences in the treatment of multiple myeloma \u2013 a discrete choice experiment of patient, carer, physician, and nurse preferences","volume":"20","author":"Fifer","year":"2020","journal-title":"BMC Cancer"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-711903","article-title":"T cells expressing an anti\u2013B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma","volume":"128","author":"Ali","year":"2016","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"New Engl J Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1182\/blood-2024-208825","article-title":"Real-world utilization of bispecific antibodies for treatment of relapsed\/refractory multiple myeloma in the US community oncology setting","volume":"144","author":"Herms","year":"2024","journal-title":"Blood"},{"key":"B39","first-page":"364\u221270","article-title":"La mesure de la disposition \u00e0 payer : La m\u00e9thode des choix discrets","volume":"23","author":"Desjeux","year":"2005","journal-title":"J d\u2019\u00e9conomie m\u00e9dicale"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0356","article-title":"CIC mutation as a molecular mechanism of acquired resistance to combined BRAF-MEK inhibition in extramedullary multiple myeloma with central nervous system involvement","volume":"25","author":"Da Vi\u00e0","year":"2020","journal-title":"Oncologist"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1628121\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T04:12:25Z","timestamp":1757995945000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1628121\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,16]]},"references-count":40,"alternative-id":["10.3389\/fonc.2025.1628121"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1628121","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,16]]},"article-number":"1628121"}}